Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites

Olivia M. Dong, Megan C. Roberts, R. Ryanne Wu, Corrine I. Voils, Nina Sperber, Kara L. Gavin, Jill Bates, Catherine Chanfreau-Coffinier, Michael Naglich, Michael J. Kelley, Jason L. Vassy, Peruvemba Sriram, C. William Heise, Salvador Rivas, Maria Ribeiro, Jennifer G. Chapman, Deepak Voora

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.

Original languageEnglish (US)
Pages (from-to)1121-1133
Number of pages13
JournalPharmacogenomics
Volume22
Issue number17
DOIs
StatePublished - Nov 2021

Keywords

  • Plan-Do-Study-Act cycles
  • Veterans
  • Veterans Affairs
  • genetic testing
  • implementation barriers
  • pharmacogenomics
  • precision medicine
  • quality improvement

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint

Dive into the research topics of 'Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites'. Together they form a unique fingerprint.

Cite this